Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GEVA's Cash to Debt is ranked higher than
87% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. GEVA: No Debt )
GEVA' s 10-Year Cash to Debt Range
Min: 0.63   Max: 58941
Current: No Debt

0.63
58941
Equity to Asset 0.95
GEVA's Equity to Asset is ranked higher than
96% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GEVA: 0.95 )
GEVA' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.98
Current: 0.95

0.36
0.98
Interest Coverage No Debt
GEVA's Interest Coverage is ranked higher than
79% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GEVA: No Debt )
GEVA' s 10-Year Interest Coverage Range
Min: 7.93   Max: 9999.99
Current: No Debt

7.93
9999.99
F-Score: 2
Z-Score: 56.39
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1899.08
GEVA's Operating margin (%) is ranked higher than
55% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. GEVA: -1899.08 )
GEVA' s 10-Year Operating margin (%) Range
Min: -6866.73   Max: 120.8
Current: -1899.08

-6866.73
120.8
Net-margin (%) -1898.49
GEVA's Net-margin (%) is ranked higher than
54% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. GEVA: -1898.49 )
GEVA' s 10-Year Net-margin (%) Range
Min: -7000   Max: 81
Current: -1898.49

-7000
81
ROE (%) -32.26
GEVA's ROE (%) is ranked higher than
75% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. GEVA: -32.26 )
GEVA' s 10-Year ROE (%) Range
Min: -105.21   Max: 52.19
Current: -32.26

-105.21
52.19
ROA (%) -30.87
GEVA's ROA (%) is ranked higher than
72% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. GEVA: -30.87 )
GEVA' s 10-Year ROA (%) Range
Min: -74.33   Max: 33.95
Current: -30.87

-74.33
33.95
ROC (Joel Greenblatt) (%) -701.94
GEVA's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. GEVA: -701.94 )
GEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2491.51   Max: 1417.12
Current: -701.94

-2491.51
1417.12
Revenue Growth (%) -91.70
GEVA's Revenue Growth (%) is ranked higher than
55% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. GEVA: -91.70 )
GEVA' s 10-Year Revenue Growth (%) Range
Min: -91.7   Max: 321.1
Current: -91.7

-91.7
321.1
EPS Growth (%) -78.50
GEVA's EPS Growth (%) is ranked higher than
51% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. GEVA: -78.50 )
GEVA' s 10-Year EPS Growth (%) Range
Min: -78.5   Max: 30.5
Current: -78.5

-78.5
30.5
» GEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GEVA Guru Trades in Q4 2013

Steven Cohen Sold Out
George Soros Sold Out
Columbia Wanger 3,217,000 sh (-0.22%)
» More
Q1 2014

GEVA Guru Trades in Q1 2014

Columbia Wanger 3,093,000 sh (-3.85%)
» More
Q2 2014

GEVA Guru Trades in Q2 2014

Columbia Wanger 3,521,000 sh (+13.84%)
» More
Q3 2014

GEVA Guru Trades in Q3 2014

Jim Simons 26,200 sh (New)
Columbia Wanger 3,927,006 sh (+11.53%)
» More
» Details

Insider Trades

Latest Guru Trades with GEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-12-31 Sold Out 0.01%$45.51 - $69.69 $ 82.1639%0
George Soros 2013-09-30 New Buy0.01%$43.26 - $62.55 $ 82.1667%17700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.25
GEVA's P/B is ranked higher than
76% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. GEVA: 5.25 )
GEVA' s 10-Year P/B Range
Min: 0.76   Max: 17.16
Current: 5.25

0.76
17.16
P/S 302.10
GEVA's P/S is ranked higher than
68% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. GEVA: 302.10 )
GEVA' s 10-Year P/S Range
Min: 0.09   Max: 2889.5
Current: 302.1

0.09
2889.5
EV-to-EBIT -13.54
GEVA's EV-to-EBIT is ranked higher than
73% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GEVA: -13.54 )
GEVA' s 10-Year EV-to-EBIT Range
Min: -153.9   Max: 40.5
Current: -13.54

-153.9
40.5
Current Ratio 21.65
GEVA's Current Ratio is ranked higher than
96% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GEVA: 21.65 )
GEVA' s 10-Year Current Ratio Range
Min: 3.17   Max: 54.89
Current: 21.65

3.17
54.89
Quick Ratio 21.65
GEVA's Quick Ratio is ranked higher than
96% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. GEVA: 21.65 )
GEVA' s 10-Year Quick Ratio Range
Min: 3.17   Max: 54.89
Current: 21.65

3.17
54.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.93
GEVA's Price/Net Cash is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. GEVA: 5.93 )
GEVA' s 10-Year Price/Net Cash Range
Min: 1.09   Max: 220.96
Current: 5.93

1.09
220.96
Price/Net Current Asset Value 5.92
GEVA's Price/Net Current Asset Value is ranked higher than
87% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. GEVA: 5.92 )
GEVA' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 170.45
Current: 5.92

1.06
170.45
Price/Tangible Book 5.36
GEVA's Price/Tangible Book is ranked higher than
81% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. GEVA: 5.36 )
GEVA' s 10-Year Price/Tangible Book Range
Min: 1.01   Max: 19.37
Current: 5.36

1.01
19.37
Price/DCF (Projected) 146.72
GEVA's Price/DCF (Projected) is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GEVA: 146.72 )
GEVA' s 10-Year Price/DCF (Projected) Range
Min: 0.01   Max: 123.68
Current: 146.72

0.01
123.68
Price/Median PS Value 46.16
GEVA's Price/Median PS Value is ranked higher than
69% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. GEVA: 46.16 )
GEVA' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 411
Current: 46.16

0.02
411
Earnings Yield (Greenblatt) -7.40
GEVA's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. GEVA: -7.40 )
GEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.5   Max: 3528.7
Current: -7.4

2.5
3528.7
Forward Rate of Return (Yacktman) 39.11
GEVA's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. GEVA: 39.11 )
GEVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -62.8   Max: 245.7
Current: 39.11

-62.8
245.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TMS1.Germany
Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.
» More Articles for NAS:GEVA

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Synageva BioPharma (GEVA): Strong Industry, Solid Earnings Estimate Revisions Nov 25 2014
Synageva Up on New Phase III Data on Sebelipase Alfa Nov 14 2014
Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults... Nov 10 2014
Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults... Nov 10 2014
SYNAGEVA BIOPHARMA CORP Financials Nov 06 2014
10-Q for Synageva BioPharma Corp. Nov 01 2014
Synageva BioPharma beats 3Q profit forecasts Oct 31 2014
Synageva BioPharma beats 3Q profit forecasts Oct 31 2014
Synageva BioPharma Reports Third Quarter 2014 Financial Results Oct 30 2014
SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 30 2014
Synageva BioPharma Reports Third Quarter 2014 Financial Results Oct 30 2014
Synageva BioPharma to Present at the Nomura Biotechnology Conference Oct 29 2014
Synageva BioPharma to Present at the Nomura Biotechnology Conference Oct 29 2014
Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting Oct 23 2014
Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting Oct 23 2014
Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For... Oct 21 2014
Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For... Oct 21 2014
Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For... Oct 21 2014
Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Oct 16 2014
Sebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral... Oct 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK